Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Xiaoqiong DongDepartment of Pharmacology, University of California, Davis, California, USA.
Ivanita StefanonDepartment of Pharmacology, University of California, Davis, California, USA.
Yi YangDepartment of Pharmacology, University of California, Davis, California, USA.
Eduardo Hertel RibeiroDepartment of Pharmacology, University of California, Davis, California, USA.
Bengt SvenssonDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Xander H T WehrensCardiovascular Research Institute, Departments of Molecular Physiology & Biophysics; Medicine (Cardiology) and Pediatrics, Baylor College of Medicine, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-5044-672X
Takeshi YamamotoDepartment of Laboratory Medicine, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.ORCID https://orcid.org/0000-0001-9334-5478
Razvan L CorneaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Robyn T RebbeckDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
Masafumi YanoDepartment of Therapeutic Science for Heart Failure in the Elderly, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan.
Program AdministrationP01HL080101 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERS, DONALD M · 2006 to 2015
$23.4M
Pathophysiological Regulation of Cardiac Myocyte RyR ChannelR01HL092097 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Donald M Bers, Robyn T Rebbeck · 2010 to 2026
$9.3M
Ryanodine receptor regulation in post-operative atrial fibrillationR01HL089598 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2007 to 2022
$6.5M
Role of Nucleoside-Diphosphate Kinase Signaling in Atrial FibrillationR01HL160992 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Xander H.T. Wehrens · 2023 to 2026
$2.1M
Mechanisms underlying atrial fibrillation associated with chronic kidney diseaseR01HL147108 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LI, NA, WEHRENS, XANDER H.T. · 2019 to 2022
$2.0M
American Heart Association (AHA) 13EIA14560061American Heart Association (AHA) 15GRNT25610022Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Edital 019/2022Espirito Santo Foundation for Research and Innovation Support TO2022-6C3F7HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) P01-080101HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL089598HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL092097HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL147108HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01-HL160992JSPS KAKENHI JP 18K15849NHLBI NIH HHS P01 HL080101NHLBI NIH HHS R01 HL089598NHLBI NIH HHS R01 HL092097NHLBI NIH HHS R01 HL147108NHLBI NIH HHS R01 HL160992Uehara Memorial Foundation (UMF) 201340224
6 · The paper itself
Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited stress-induced arrhythmogenic disease often caused by point variants in the cardiac ryanodine receptor (RyR2) that enhance diastolic sarcoplasmic reticulum (SR) Ca
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Catecholaminergic polymorphic ventricular tachycardia-linked ryanodine receptor variants exhibit domain-specific calcium leak and calmodulin affinity properties. · full record | OpenQuestion